Developing breakthrough oncology drug candidates

Sprint Bioscience, in collaboration with MAX IV, has been awarded approximately 940,000 kronor in funding from Vinnova for a joint research project on alternative methods for fragment screening, with the aim of improving future drug development programs. The project combines Sprint Bioscience’s expertise in fragment-based drug discovery with MAX IV’s world-leading research infrastructure. ”The fact that Vinnova is awarding funding to this project together with MAX IV […]

The Flemingsberg Science Foundation is a neutral actor in the regional development of southern Stockholm, with a mission to promote and spearhead the development of knowledge-intensive activities in Flemingsberg. Part of Flemingsberg Science is the Life Science Cluster Flemingsberg, an ERDF project aimed at fostering growth in the life sciences. Read more about the initiative here. In Flemingsberg…

Sprint Bioscience summarizes below the company’s upcoming meetings with potential partners and investors during the second half of 2026. The list is subject to change and is available on the company’s website. International partnering conferences: September 8–9, 2026 Nordic Life Science Days, Stockholm, Sweden https://nlsdays.com/ September 14–16, 2026 IPLS, International Partnering in Life Science Society Annual Conference, Stockholm, Sweden, https://ipls.online/events/, October 7–9, 2026, Bio Japan, Yokohama, Japan, https://jcd-expo.jp/en/, November 9–11 […]

Sprint Bioscience announced in a press release on July 23 that the company has entered into an agreement with Lilly TuneLab, a collaborative, AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining TuneLab, Sprint Bioscience intends to strengthen and accelerate the development of its portfolio through access to advanced models for…